Notice to Readers Marketing of Human Diploid Cell Strain
Rabies Vaccine
Recently completed negotiations between Wistar Institute, Wyeth
Laboratories, and Merieux Institute have resulted in an agreement
whereby Merieux Institute is now able to market its vaccine
directly
to the private medical sector. Because some states may wish to
continue their existing distribution systems, Merieux Institute
representatives will be contacting state health departments within
the
next 2 weeks to determine how each state wishes to have the Merieux
human diploid cell strain (HDCS) vaccine distributed.
For those states that wish to relinquish the distribution of
vaccine in favor of private-sector sales, the vaccine will be
available for purchase through either the Merieux offices in Miami,
Florida, or a distribution point nearer the purchaser.
Reported by Enteric and Neurotropic Viral Diseases Br, Center for
Infectious Diseases, CDC.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
